El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Cerus Corp
Cerrado
SectorSalud
1.93 -4.93
Resumen
Variación precio
24h
Mínimo
1.92
Máximo
2.03
Ingresos | 5.7M -19K |
|---|---|
Ventas | 5.1M 58M |
Margen de beneficio | -0.036 |
Empleados | 614 |
EBITDA | -4.3M -1.8M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +145.1% upside |
Próximas Ganancias | 30 abr 2026 |
|---|
Capitalización de Mercado | 29M 486M |
|---|---|
Apertura anterior | 6.86 |
Cierre anterior | 1.93 |
Puntuación técnica
By Trading Central
Confianza
Weak Bullish Evidence
Cerus Corp Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Cerus Corp Esperado
Precio Objetivo
By TipRanks
145.1% repunte
Estimación a 12 meses
Media 5 USD 145.1%
Máximo 5 USD
Mínimo 5 USD
De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cerus Corp Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Cerus Corp
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Live chat